ANAND ET AL. Appl. No. 10/563,042 Attv. Ref.: 620-406

Amendment August 14, 2008

AMENDMENTS TO THE ABSTRACT:

Please insert the Abstract of the Disclosure which is on the attached sheet in place of the Abstract added with the Amendment of January 3, 2006. The following reproduction of the attached shows the changes from the previous version by underlining and strike-through text:

ABSTRACT OF THE DISCLOSURE

This invention relates to the use of anti-cancer agents that inhibit mitotic spindle assembly in target cells, including taxanes such as paclitaxel, and in particular to methods and <u>structures means</u>-for predicting and/or reducing the resistance of cancer cells to such agents. Over-expression of aurora kinases, such as Aurora A, mediates resistance to such anti-cancer agents and the resistance of a cancer cell may be reduced by inhibiting aurora kinases and/or predicted by measuring the expression or activity of aurora kinases within the cell